Company Profile
Tenaya Therapeutics Stock Price, News & Catalysts
- Ticker:
- TNYA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.70 USD (+0.98%)
Close
Last updated: August 21, 2026
171M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, TNYA closed up 0.98% at $0.6973. No new same-company headline was identified in the current news window.
Company overview
Genetically Informed Cardiac Therapies
Tenaya Therapeutics develops gene therapies and small molecules that address underlying drivers of inherited and prevalent heart disease.
TN-201
TN-201 is an AAV gene therapy for hypertrophic cardiomyopathy caused by MYBPC3 mutations. The Phase 1b/2 MyPEAK-1 study is evaluating two dose cohorts in adults.
TN-401
TN-401 is an AAV gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. RIDGE-1 is assessing safety, cardiac biomarkers and early measures of disease activity.
TN-301
TN-301 is a selective HDAC6 inhibitor with potential applications in heart failure with preserved ejection fraction, Duchenne muscular dystrophy and other cardiac or muscular disorders.
Discovery Collaborations
Tenaya combines internal target discovery with external collaborations, including work with Alnylam to identify and validate genetic targets for cardiovascular disease.
Future catalysts
- One-year Cohort 1 and initial Cohort 2 RIDGE-1 data for TN-401 at ASGCT 2026.
- Updated Cohort 1 and Cohort 2 MyPEAK-1 data for TN-201 in the second quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Tenaya Therapeutics (TNYA)?
Tenaya Therapeutics (TNYA) most recently closed at 0.70 USD, a +0.98% move versus the previous session.
What is the market cap of Tenaya Therapeutics (TNYA)?
Tenaya Therapeutics currently has a market capitalization of 171M USD on BioPharmSignal.
What does Tenaya Therapeutics do?
Genetically Informed Cardiac Therapies Tenaya Therapeutics develops gene therapies and small molecules that address underlying drivers of inherited and prevalent heart disease. TN-201 TN-201 is an AAV gene therapy for hypertrophic cardiomyopathy caused by MYBPC3 mutations. The Phase 1b/2 MyPEAK-1 study is evaluating two dose cohorts in adults. TN-401 TN-401...
On which exchange is TNYA stock listed?
Tenaya Therapeutics (TNYA) is associated with NASDAQ, United States, Biopharma.
What is TN-201?
Updated Cohort 1 and Cohort 2 MyPEAK-1 data for TN-201 in the second quarter of 2026.
Which conditions is Tenaya Therapeutics targeting with TN-201?
Tenaya Therapeutics is associated with cardiovascular disease, genetic disease based on its company overview and current catalyst commentary.
How does Tenaya Therapeutics describe recent progress with TN-201?
Updated Cohort 1 and Cohort 2 MyPEAK-1 data for TN-201 in the second quarter of 2026.
What is TN-401?
TN-401 TN-401 is an AAV gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.